A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM)

Clinical Trial ID NCT01028222

Rank	Title	Journal	Year	PubWeight™‹?›
1	From genes to drugs: targeted strategies for melanoma.	Nat Rev Cancer	2012	2.46
2	Melanoma: new insights and new therapies.	J Invest Dermatol	2012	1.54
3	Treatment of cutaneous melanoma: current approaches and future prospects.	Cancer Manag Res	2010	1.01
4	Targeting the RAS pathway in melanoma.	Trends Mol Med	2011	0.98
5	Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.	J Carcinog	2010	0.97
6	Targeting drivers of melanoma with synthetic small molecules and phytochemicals.	Cancer Lett	2015	0.88
7	What is new in the treatment of advanced melanoma? State of the art.	Contemp Oncol (Pozn)	2012	0.88
8	Targeted agents for the treatment of metastatic melanoma.	Onco Targets Ther	2012	0.88
9	The current state of targeted therapy in melanoma: this time it's personal.	Semin Oncol	2012	0.86
10	Biomarkers as key contributors in treating malignant melanoma metastases.	Dermatol Res Pract	2011	0.79
11	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).	Oncologist	2015	0.75